drugs used to treat breast cancer for which a dose-response relationship has been demonstrated. 5,6 Hematological toxicity, particularly for alkylating agents is a limiting factor The importance of dose-intensity has been suggested in breast cancer. The aim of this study was to evaluate the in the escalation of dose-intensity. Hematopoietic growth factors have been successfully used to decrease myeloid feasability of a high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and toxicity in standard regimens 7,8 and to increase dose and dose-intensity.
) at 3 week intervals. Apheresis was performed after the first appears to be a limiting toxicity, independent of neutropenia, to high-dose intensity regimen. Peripheral blood procycle and if necessary after the second cycle. Stem cells were reinfused after the third and fourth cycles. G-CSF genitors have the capacity to enhance hematological recovery after myeloablative regimens, particularly for the was started on day 3 of each cycle (5 g/kg/day) and was stopped the day before the last apheresis or when platelet lineage 11 and decrease myelotoxicity of repetitive high-dose regimens.
12-15
absolute neutrophil count was above 0.5 × 10 9 /l. Median received dose-intensity was respectively 25 mg/m 2 /week The aim of this study was to increase dose-intensity and total cyclophosphamide dose 5-fold and by 1.25 dose-inten-(range 22-26) and 1000 mg/m 2 /week (range 904-1065) for doxorubicin and cyclophosphamide. Grade IV sity and total dose of doxorubicin in the standard regimen associating cyclophosphamide (600 mg/m 2 × 4) and thrombocytopenia occurred in 8% of cycles. Two patients needed platelets and 12 red cell transfusion. Fifdoxorubicin (60 mg/m 2 × 4). 16 We report here tolerance of 100 cycles of such a regimen in 25 patients with breast teen patients were readmitted for a median duration of 4 days (range 1-7). We have established a safe, outcancer and show that with the use of both G-CSF (filgrastim) and peripheral blood progenitors, a major dosepatient, high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood escalation can be routinely achieved in an outpatient setting. stem cells which can be submitted for comparison with the current standards. Keywords: stem cells; breast cancer; chemotherapy
Patients and methods
Patients' eligibility and characteristics The increase in dose and dose-intensity (amount of chemotherapy per unit of time) may increase response in various
Patients with poor prognosis non-metastatic breast cancer solid tumors including breast cancer. 1 Retrospective studies were enrolled in this study. Patient eligibility requirements have pointed to the impact of dose-intensity, either on disincluded women aged at least 18 years, non-menopausal, ease-free survival or survival, in adjuvant chemotherapy with non-metastatic histologically proven breast cancer and regimen.
2,3 A prospective study from CALGB 4 tested three more than three involved homolateral axillary lymph nodes. levels of dose-intensity in an association of doxorubicin-WHO performance status had to be 0, 1 or 2, neutrophil cyclophosphamide-5 fluorouracil in node-positive breast count above 1.5 × 10 9 /l, platelet count above 100 × 10 9 /l, cancer with a benefit in progression free survival and surtotal bilirubin, ASAT, ALAT and serum creatinine less than vival for patients receiving the two highest dose-intensity 1.25 times the upper limit of normal range. Patients with levels. In all these studies, dose-intensity ranged from 0.75 inflammatory breast cancer, contralateral or supra-clavicuto 2 of standard levels and total doses were low. lar involved lymph nodes were excluded from the study as Doxorubicin and cyclophosphamide are two of the major were all cases of relapse of breast cancer. The study was approved by the local ethical committee and all patients were asked to give written informed consent.
radionuclide ventriculography or echocardiography, chest three bags: two containing at least 2 × 10 6 CD34 + cells/kg and one for back-up. Blood stem cells were reinfused on X-ray, liver ultrasonography and bone scan.
Between September 1993 and September 1995, 25 nonday 3 of cycle 3 and cycle 4 (at least 2 × 10 6 CD34 + cells/kg each infusion). menopausal women with poor prognosis breast cancer were enrolled in the study. Their median age was 45 years (range Apheresis was started when the absolute number of CD34 + cells in the peripheral blood rose to 20/l. Apheresis 27-57). Twenty-three patients had a ductal invasive carcinoma and two a lobular. The median number of positive was performed using the Cobe Spectra automated processor (Cobe, Denver, CO, USA), using an ACD/blood ratio of homolateral axillary lymph nodes was five (range 4-8).
Initial surgery consisted of a modified mastectomy with approximately 1/8 to 1/12. Two blood masses were treated during each 3 h session. axillary dissection for one patient and tumorectomy with axillary dissection for the other 24. All 25 patients received the four cycles of chemotherapy.
Supportive care: Anti-emetic therapy consisted of ondansetron 8 mg and dexamethasone 20 mg i.v., infused 30 min before chemotherapy. Patients were discharged from hospiTreatment tal after chemotherapy. Blood stem cell collection and reinChemotherapy ( Figure 1 ): After initial surgery, patients fusion were performed in a conventional hospital unit or in were treated with four cycles of high-dose cyclophosphaman outpatient clinic. No antibiotic prophylaxis was given ide (3000 mg/m 2 ) and doxorubicin (75 mg/m 2 ). Chemobut patients were hospitalized if they became febrile therapy was scheduled every 21 days and administered dur-(Ͼ38°C) to receive i.v. antibiotics. Red blood cells were ing a 24 h hospitalization. Doxorubicin was infused as a transfused when hemoglobin was р8 g/dl or for anemia 15 min infusion and cyclophosphamide as a 1 h infusion, symptoms and platelets were transfused for hemorrhagic both on day 1. Patients were hydrated with 3 l/m 2 of a symptoms. All blood products, except blood stem cells, semi-saline solution.
were irradiated at 25 Gy. Chemotherapy was administered if absolute neutrophil count (ANC) was у1.5 × 10 9 /l and platelet count Toxicity: Once per course (D1), physical examination was у100 × 10 9 /l. If the patient's neutrophil and platelet count carried out and WHO performance status, vital signs, EKG, did not meet these criteria on day 21 chemotherapy was complete blood count (CBC) and differential, liver funcdelayed until adequate count recovery. No dose-reduction tion, creatinine and coagulation profile were obtained. Durwas planned. If, on day 35 of one cycle, chemotherapy was ing the treatment period, CBC and differential were not possible the patient was excluded from the study.
obtained three times a week. At the end of chemotherapy For each drug, dose intensity was calculated as the total the pre-treatment evaluation, except radionuclide bone amount of chemotherapy given, divided by the body surface scan, was repeated with toxicities being assessed according area and the delay (in weeks) between day 1 of cycle 1 and to WHO criteria. 3 weeks after day 1 of cycle 4. Relative dose-intensity (RDI) was the result of dose intensity divided by the theoretical dose-intensity.
Results

G-CSF and apheresis (cell procedure): G-CSF (filgrastim;
Stem cell collection Amgen, USA) was administered subcutaneously at a daily dosage of 5 g/kg (maximum 300 g per day) from day For the first patients, stem cells were collected systemati-3 of each cycle until the day before the last apheresis or cally with two sets of apheresis after the first cycle of until ANC reached 0.5 × 10 9 /l on 3 consecutive days for chemotherapy and one or two sets of apheresis after the cycles without apheresis.
second. After six patients had been treated, apheresis was At the beginning of the study, apheresis was systematistopped as soon as 6 × 10 6 CD34 + cells/kg were collected. cally done after the first and the second cycle of chemoTwo sets of apheresis were done for 18 patients and one therapy, and was stopped as soon as the collection of set for seven after the first cycle of chemotherapy, and two CD 34 + cells exceeded 6 × 10 6 /kg. Cells were divided into sets for two patients and one for five patients after the second cycle. The median number of CD34 + cells collected per kg was 9.54 × 10 6 (range 4.26-24.61) after the first cycle and 1.88 × 10 6 (range 1.39-13.67) after the second cycle. The number of 6 × 10 6 CD34 + cells/kg was obtained for 24 out of 25 patients after the first cycle of chemotherapy. All 25 patients received local treatment after chemotherapy, which consisted of surgery followed by radiotherapy for nine patients and radiotherapy alone for 16 patients. The first treatment was performed in a median of and 23 out of 25 a grade 4. Grade 4 neutropenia occurred 42 days (range 27-71) after day 1 of cycle 4 in the case in 66% of the 100 cycles of chemotherapy administered.
Hematological toxicity ( ) ( )
of surgery and 36 days (range 24-50) after day 1 of cycle Incidence of grade 4 neutropenia from cycle 1 to 4 was 4 in the case of radiotherapy. respectively 72, 56, 72 and 64%.
We did not see any increase in the incidence or duration of neutropenia from cycle 1 to cycle 4. Thirty-four cycles Discussion of chemotherapy were followed by hospitalization for treatment-related complications, which were, in 90% of cases, Twenty-five patients received 100 cycles of high-dose febrile neutropenia. Only one was documented with a cyclophosphamide and doxorubicin with supporting G-CSF corynebacterium. Ten patients did not need any hospitaliz-(filgrastim) and blood stem cells. This study was designed ation for toxicity during the four cycles.
to evaluate the toxicity of an outpatient high-dose intensity doxorubicin-cyclophosphamide regimen which could be Thrombocytopenia ( Table 2) : Toxicity of the platelet lingiven as adjuvant treatment for breast cancer. The main eage was very mild. Thirteen patients had no grade III toxicity of the regimen was hematologic toxicity. As thrombocytopenia. No patient experienced grade IV thromexpected with the use of G-CSF (filgrastim) grade IV neubocytopenia in cycle 1 but the incidence of this event was tropenia was of short duration with a maximum of 5 days. 8% in cycle 2, 16% in cycle 3 and 8% in cycle 4. There Neutropenia delayed chemotherapy for only one patient. was no increase of duration of extreme thrombocytopenia Febrile neutropenia occurred in 30% of cycles and led to from cycle 2 to cycle 4. brief hospitalization. This problem was always managed in a standard oncology medical unit and bacterial docuAdditional toxicity: Other grade у2 toxicities were essenmentation occurred only once. There was little need for tially nausea and vomiting (36% of cycles), asthenia (14% platelet transfusion (2/25 patients) but requirement for red of cycles), mucositis (10% of cycles) and bone pain. No blood cells was relatively high (12/25 patients). When hemliver toxicity grade у2, acute cardiac toxicity or decrease atopoietic growth factors are used to increase dose intensity in left ventricular ejection fraction occurred.
of conventional chemotherapy regimens, thrombocytopenia and the requirement for platelet transfusion is generally Treatment administration cumulative. 8, 10, 17, 18 Recently, a dose-finding study of very high-dose CHOP for non-Hodgkin's lymphomas with GTwenty-five patients received 100 cycles of chemotherapy.
CSF but without peripheral blood progenitors clearly identNo dose-reduction, either of cyclophosphamide or doxorubified thrombocytopenia as the dose-limiting toxicity. 19 In icin, occurred. The median received dose-intensity for the study carried out by Shipp et al, thrombocytopenia cyclophosphamide was 1000 mg/m 2 /week (range 904-increased with doses and, in each step, with cycles of chemotherapy establishing the maximum tolerable doses of cyclophosphamide and doxorubicin at respectively 4000 ies using G-CSF or GM-CSF alone. However, one of the risks in using peripheral blood progenitors is the mobiliz- point, the use of peripheral blood progenitors could be crit- Other groups have increased the dose-intensity of conven- dose-escalation is limited by hematological toxicity, parti-
